Navigating A New Therapeutic Era for HCC: Expert Review of New Agents and Guideline Recommendations

Navigating A New Therapeutic Era for HCC: Expert Review of New Agents and Guideline Recommendations (June 2019)

Sunday, June 2, 2019 in Chicago, Illinois
Dinner -- Radisson Blu Aqua Hotel, Chicago, 6:30 PM CT
Atlantic Ballroom B


Welcome and Introduction

Treating locally advanced, inoperable HCC

Initial systemic therapy options for advanced, unresectable HCC

Optimal treatment sequence following disease progression after initial therapy

Best practices for collaborative clinical decision making and key factors into incorporating new agents into clinical practice for HCC at all stages of disease 

Final Thoughts and Audience Question and Answer Session


Thomas A. Abrams, MD

Assistant Professor
Harvard Medical School
Director, Liver Tumor Center
Dana-Farber Cancer Institute
Boston, Massachusetts

R. Kate Kelley, MD

Associate Professor
Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California

Stacey Stein, MD

Assistant Professor of Medicine
Department of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut

Goal Statement
The goal of this activity is to improve participants’ competence in applying the latest treatment approaches and interdisciplinary collaborative strategies towards optimal care of patients with HCC.

Target Audience 
This program is intended for physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with HCC.

Learning Objectives 

  • Explore first-line treatment options for individual patients with advanced HCC, considering the available clinical evidence, known agent toxicity/ tolerability profiles, expert recommendations, and patient preferences
  • Apply clinical evidence and expert recommendations to select optimal treatment for patients with HCC that has progressed on or after 1 or multiple lines of therapy
  • Plan therapeutic strategies that optimize the sequence of therapies to provide the best outcome to patients with HCC
  • Counsel patients to help them understand their treatment options and to be proactive, knowledgeable participants in their care
  • Employ effective collaborative strategies to ensure the best possible application of the latest HCC treatment approaches
  • Become familiar with the design of ongoing clinical trials for novel HCC treatment strategies, and counsel appropriate patients about availability and participation


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 2.0 contact hours.


NCCN designates this knowledge-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. UAN: JA4008196-9999-19-005-L01-P

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID.

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.